SOURCE: United Health Products Inc.

March 09, 2016 08:30 ET

United Health Products Inc. Announces Exclusive Distributor for India

HENDERSON, NV--(Marketwired - Mar 9, 2016) - United Health Products Inc. (OTCQB: UEEC) announced that it has entered into an exclusive distribution contract with CJ Global Capital LLC for India. The exclusive contract has a licensing fee and minimum yearly purchase requirements to maintain the rights to exclusivity to India for all of United Health Products Inc. HemoStyp® products. India's current health care industry is estimated to be USD 120 Billion and reach USD 230 Billion by 2020, with USD 5.5 Billion in Wound Care. Indian Government Expenditure on health care is the highest amongst all the developing countries. The expenses of this industry comprise 5.25% of the GDP. India is the second most populous country in the world, with over 1.277 billion people (2015), more than a sixth of the world's population.

About CJ Global Capital LLC
CJ Global Capital LLC is a private international investment group headquartered in the United States specializing in projects involving patented products, new technologies, and large scale commercial real estate development. CJGC sales and marketing efforts for wholesaling will be led by David Champion, Marketing Director of Asia Pacific for Apollo RT Co., Ltd. Apollo RT Co. is a new Japanese owned company with manufacturing in China. David Champion is responsible for marketing and strategy for the Asian Market. In addition, David is Country Director for Apollo RT Co. business in Korea and Canada. David lived in India in the late 1990's and was employed by a company which is now part of GE Healthcare. He worked 13 years for Tyco Healthcare (later known as Covidien) in urological products (including incontinence products) and wound care products. CJGC various projects total USD 1 billion.

About United Health Products Inc.
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact Information

  • Company Contact:
    United Health Products Inc.
    ph.877-358-3444

    IR Contact:
    PCG Advisory Group